Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages
Bisphosphonates drugs target the skeleton and are used globally for the treatment of common bone disorders. Nitrogen-containing bisphosphonates act by inhibiting the mevalonate pathway in bone-resorbing osteoclasts but, surprisingly, also appear to reduce the risk of death from pneumonia. We overtur...
Main Authors: | Marcia A Munoz, Emma K Fletcher, Oliver P Skinner, Julie Jurczyluk, Esther Kristianto, Mark P Hodson, Shuting Sun, Frank H Ebetino, David R Croucher, Philip M Hansbro, Jacqueline R Center, Michael J Rogers |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2021-12-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/72430 |
Similar Items
-
Influence of Bisphosphonates on Alveolar Bone Loss around Osseointegrated Implants
by: Vivek, et al.
Published: (2024-12-01) -
Bone sparing effects of bisphosphonates in cyclosporine-induced alveolar bone loss: An animal study
by: Sneha R Bhat, et al.
Published: (2020-01-01) -
Bisphosphonates: An update
by: Nalliappan Ganapathy, et al.
Published: (2012-01-01) -
Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency
by: Marcia A. Munoz, et al.
Published: (2019-08-01) -
Bisphosphonate-related osteonecrosis of the jaw: An insight
by: Shalini Kapoor, et al.
Published: (2013-01-01)